Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/OTT.S119980 http://scihub22266oqcxt.onion/10.2147/OTT.S119980 C5106236!5106236 !27853381     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27853381 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27853381 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Onco+Targets+Ther 2016 ; 9 (ä): 6873-6884 Nephropedia Template TP {{tp|p=27853381 |t=2016. Hürthle cell carcinoma: current perspectives |pdf=|usr=}}{{27853381 }} gab.com Text Hürthle cell carcinoma: current perspectives JO: Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=27853381 #FOAvip Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC. Twit Text FOAVip Hürthle cell carcinoma: current perspectives ????Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=27853381 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27853381 #FOAvip English Wikipedia <ref>{{Cite pmid|27853381 }}</ref> Hürthle cell carcinoma: current perspectives #MMPMID27853381 Ahmadi S ; Stang M ; Jiang XS ; Sosa JA Onco Targets Ther 2016[]; 9 (ä): 6873-6884 PMID27853381 show ga Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC. äHürthle cell carcinoma: current perspectives (epmc).pdf DeepDyve Pubget Overpricing